Last reviewed · How we verify
Dose-adjusted SK-1403 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Dose-adjusted SK-1403 (Dose-adjusted SK-1403) — Sanwa Kagaku Kenkyusho Co., Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Dose-adjusted SK-1403 TARGET | Dose-adjusted SK-1403 | Sanwa Kagaku Kenkyusho Co., Ltd. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Dose-adjusted SK-1403 CI watch — RSS
- Dose-adjusted SK-1403 CI watch — Atom
- Dose-adjusted SK-1403 CI watch — JSON
- Dose-adjusted SK-1403 alone — RSS
Cite this brief
Drug Landscape (2026). Dose-adjusted SK-1403 — Competitive Intelligence Brief. https://druglandscape.com/ci/dose-adjusted-sk-1403. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab